12:00 AM
Sep 12, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Savaysa: Phase IIIb data

Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan
Product: Savaysa ( Lixiana - EU) edoxaban (DU-176b)
Business: Cardiovascular
Molecular target: Factor Xa
Description: Oral Factor Xa inhibitor
Indication: Prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF)
Endpoint: Composite of stroke, systemic embolism, myocardial infarction (MI) and cardiovascular mortality and composite of major and clinically-relevant non-major bleeding; composite of stroke, systemic embolism, MI, cardiovascular mortality...

Read the full 312 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >